Ignite Creation Date:
2024-05-06 @ 7:14 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05932550
Status:
COMPLETED
Last Update Posted:
2023-07-06
First Post:
2023-06-28
Brief Title:
Safety of Maraviroc for Post-stroke Depression
Sponsor:
Tel-Aviv Sourasky Medical Center
Organization:
Tel-Aviv Sourasky Medical Center
Study Overview
Official Title:
Safety of Maraviroc for Post-stroke Depression Proof-of-concept
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MRV-PSD
Brief Summary:
Post-stroke depression PSD is a barrier to effective rehabilitation and recovery after stroke Current treatment options are limited and there is an unmet need for specific and effective therapeutic options
Objective To examine the safety and efficacy of Maraviroc a CCR5 antagonist as a possible add-on treatment option for PSD in an open-labeled proof-of-concept clinical trial
Design Setting and Participants A 10-week trial of daily oral 300 mg Maraviroc in ten patients with subcortical stroke suffering from PSD Follow-up eight weeks after completing treatment
Main Outcome Measure A change in the Montgomery-Asberg Depression Rating Scale MADRS
Objective To examine the safety and efficacy of Maraviroc a CCR5 antagonist as a possible add-on treatment option for PSD in an open-labeled proof-of-concept clinical trial
Design Setting and Participants A 10-week trial of daily oral 300 mg Maraviroc in ten patients with subcortical stroke suffering from PSD Follow-up eight weeks after completing treatment
Main Outcome Measure A change in the Montgomery-Asberg Depression Rating Scale MADRS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None